StemRIM issues restricted stock, projects continued R&D through 2026

StemRIM Inc. reported a net loss of JPY 527,718 thousand for the first quarter ended October 31, 2025, with no operating revenue. The company’s total assets decreased by JPY 437,568 thousand to JPY 7,081,091 thousand, primarily due to a reduction in cash and deposits. Total liabilities increased by JPY 58,755 thousand to JPY 263,186 thousand, driven by increases in accounts payable and advances received.

Concurrently, StemRIM completed the payment for the issuance of 545,000 new ordinary shares as restricted stock compensation, totaling JPY 151,510,000. These shares were allocated to directors (495,000 shares) and auditors (50,000 shares) at an issue price of JPY 278 per share, effective December 10, 2025.

For the fiscal year ending July 31, 2026, StemRIM anticipates continued progress in clinical trials and licensing negotiations for Redasemtide and next-generation candidates TRIM3 and TRIM4. The company forecasts cash R&D expenses between JPY 1,300 million and JPY 1,700 million, and general and administrative expenses between JPY 230 million and JPY 310 million. Potential upfront and milestone payments from partnerships could also impact cash flow.